Denali Therapeutics Inc. Debt Securities, Available-for-sale, Amortized Cost
Denali Therapeutics Inc. (DNLI) had Debt Securities, Available-for-sale, Amortized Cost of $740.09 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $740.09M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $664.17M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $759.84M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $780.49M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $740.09M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $664.17M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $759.84M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $780.49M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $834.92M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $994.43M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $1.01B 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.19B 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.27B 10-Q · filed 2024-08-01 |
| 2024-03-31 | $1.37B 10-Q · filed 2024-05-07 |
| 2023-12-31 | $906.41M 10-K · filed 2025-02-27 |
| 2023-09-30 | $969.45M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $1.06B 10-Q · filed 2023-08-08 |
| 2023-03-31 | $1.22B 10-Q · filed 2023-05-08 |
| 2022-12-31 | $1.12B 10-K · filed 2024-02-28 |
| 2022-09-30 | $998.94M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $1.02B 10-Q · filed 2022-08-08 |
| 2022-03-31 | $1.11B 10-Q · filed 2022-05-05 |
| 2021-12-31 | $999.53M 10-K · filed 2023-02-27 |
| 2021-09-30 | $964.26M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $915.79M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $1.02B 10-Q · filed 2021-05-05 |
| 2020-12-31 | $995.15M 10-K · filed 2022-02-28 |
| 2020-09-30 | $630.13M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $418.67M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $388.15M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $375.09M 10-K · filed 2021-02-26 |
| 2019-09-30 | $419.26M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $470.31M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $543.04M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $535.71M 10-K · filed 2020-02-27 |
| 2018-09-30 | $474.89M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $519.70M 10-Q · filed 2018-08-09 |
| 2017-12-31 | $248.97M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |